

# Apple Health PDL Archived Drug Classes

# Archived Drug Classes

---

- ▶ ANTIBIOTICS : ANTI-INFECTIVE AGENTS - MISC – INHALED (No updates)
- ▶ ANTIDEPRESSANTS : ALPHA-2 RECEPTOR ANTAGONISTS (TETRACYCLICS) (No updates)
- ▶ ANTIDEPRESSANTS : MONOAMINE OXIDASE INHIBITORS (MAOI) (No updates)
- ▶ ANTIDEPRESSANTS : NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (No updates)
- ▶ ANTIDEPRESSANTS : SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) (No updates)
- ▶ ANTIDEPRESSANTS : SELECTIVE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI) (No updates)
- ▶ ANTIDEPRESSANTS : SEROTONIN MODULATORS (No updates)
- ▶ ANTIDEPRESSANTS : TRICYCLIC AGENTS (No updates)

# Archived Drug Classes

---

- ▶ ANTIDIABETICS : ALPHA-GLUCOSIDASE INHIBITORS (No updates)
- ▶ ANTIDIABETICS : BIGUANIDES
  - ▶ Recalls of Metformin ER due to NDMA impurities from various manufacturers
- ▶ ANTIDIABETICS : DIABETIC OTHER
  - ▶ Baqsimi
    - ▶ FDA Approval July 2019
    - ▶ Dry nasal spray for hypoglycemia
  - ▶ Gvoke
    - ▶ FDA Approval September 2019
    - ▶ Premixed autoinjector for hypoglycemia
- ▶ ANTIDIABETICS : DOPAMINE RECEPTOR AGONISTS (No updates)

# Archived Drug Classes

---

- ▶ ANTIDIABETICS : MEGLITINIDE ANALOGUES (No updates)
- ▶ ANTIDIABETICS : SULFONYLUREAS (No updates)
- ▶ ANTIDIABETICS : THIAZOLIDINEDIONES (No updates)
- ▶ ANTIDOTES AND SPECIFIC ANTAGONISTS : CHELATING AGENTS (No updates)
- ▶ ANTIFUNGALS : INJECTABLE (No updates)
- ▶ ANTIFUNGALS : ORAL (No updates)
- ▶ ANTIFUNGALS : VAGINAL (No updates)

# Archived Drug Classes

---

## ▶ ANTIHYPERLIPIDEMICS : ANTIHYPERLIPIDEMICS MISC

### ▶ Vascepa (icosapent ethyl)

- ▶ Dec 2019- Label expansion for use as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG levels 150 mg/dL or higher
  - ➔ Patients must have established cardiovascular disease
  - ➔ Diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

### ▶ Nexlizet (Bempedoic acid + ezetimibe)

- ▶ FDA approval: February 2020
- ▶ Indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C

# Archived Drug Classes

---

- ▶ ANTIHYPERLIPIDEMICS : BILE ACID SEQUESTRANTS (No updates)
- ▶ ANTIHYPERLIPIDEMICS : FIBRIC ACID DERIVATIVES (No updates)
- ▶ ANTIHYPERLIPIDEMICS : HMG COA REDUCTASE INHIBITORS (STATINS) AND COMBINATIONS (No updates)
- ▶ ANTIHYPERTENSIVES : ACE INHIBITOR COMBINATIONS (No updates)
- ▶ ANTIHYPERTENSIVES : ACE INHIBITORS (No updates)
- ▶ ANTIHYPERTENSIVES : ANGIOTENSIN II RECEPTOR BLOCKER COMBINATIONS (No updates)
- ▶ ANTIHYPERTENSIVES : ANGIOTENSIN II RECEPTOR BLOCKERS (No updates)
- ▶ ANTIHYPERTENSIVES : ANTIADRENERGIC COMBINATIONS (No updates)

# Archived Drug Classes

---

- ▶ ANTIHYPERTENSIVES : ANTIADRENERGICS (No updates)
- ▶ ANTIHYPERTENSIVES : BETA-BLOCKER COMBINATIONS (No updates)
- ▶ ANTIHYPERTENSIVES : BETA-BLOCKERS (No updates)
- ▶ ANTIHYPERTENSIVES : CALCIUM CHANNEL BLOCKER COMBINATIONS (No updates)
- ▶ ANTIHYPERTENSIVES : CALCIUM CHANNEL BLOCKERS
  - ▶ Conjupri (Levamlodipine maleate)
    - FDA Approval: December 2019
    - Indicated for treatment of hypertension in adults and pediatric patients 6 years and older

# Archived Drug Classes

---

- ▶ ANTIHYPERTENSIVES : OTHER (No updates)
- ▶ ANTIHYPERTENSIVES : VASODILATORS (No updates)
- ▶ ANTIPARASITICS : AMEBICIDES (No updates)
- ▶ ANTIPARASITICS : ANTHELMINTICS
  - ▶ Egaten (Triclabendazole)
    - FDA Approval: February 2019
    - Indicated for the treatment of fascioliasis in patients six years of age and older
- ▶ ANTIPARASITICS : ANTIMALARIALS (No updates)



# Archived Drug Classes

---

## ▶ ANTIPARASITICS : ANTIPROTOZOAL AGENTS

### ▶ Lampit (Nifurtimox)

- ▶ FDA Approval: August 2020
- ▶ Indicated for pediatric patients (birth to less than 18 years old and weighing at least 2.5 kg) for treatment of Chagas disease caused by *Typanosoma cruzi*

## ▶ ANTIPARASITICS : SCABICIDES AND PEDICULICIDES (No updates)

## ▶ ANTIPARKINSON AGENTS : ANTICHOLINERGICS (No updates)

## ▶ ANTIPARKINSON AGENTS : COMT INHIBITORS

### ▶ Ongentys (Opicapone)

- ▶ FDA Approval: April 2020
- ▶ Indicated as adjunctive treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing "off" episodes

# Archived Drug Classes

---

- ▶ ANTIPSYCHOTICS / ANTIMANIC AGENTS : ANTIMANIC AGENTS (No updates)
- ▶ ANTIPSYCHOTICS / ANTIMANIC AGENTS : ANTIPSYCHOTICS - 1ST GENERATION (No updates)
- ▶ ANTIVIRALS : CMV AGENTS (No updates)
- ▶ ANTIVIRALS : HEPATITIS B AGENTS (No updates)
- ▶ ANTIVIRALS : HERPES AGENTS (No updates)
- ▶ ANTIVIRALS : RESPIRATORY SYNCYTIAL VIRUS (RSV) AGENTS (No updates)
- ▶ ASTHMA AND COPD AGENTS : BETA AGONISTS - LONG ACTING (No updates)
- ▶ ASTHMA AND COPD AGENTS : BETA AGONISTS - ORAL (No updates)

# Archived Drug Classes

---

- ▶ ASTHMA AND COPD AGENTS : BETA AGONISTS - SHORT ACTING (No updates)
- ▶ ASTHMA AND COPD AGENTS : LEUKOTRIENE MODIFIERS
  - ▶ Montelukast- FDA requiring boxed warning be added to prescribing information to describe seriously mental health side effects. Recommend to be reserved to treat allergic rhinitis in patients who are not treated effectively or cannot tolerate other allergic medications
- ▶ ASTHMA AND COPD AGENTS : XANTHINES (No updates)
- ▶ BONE DENSITY REGULATORS – CALCITONINS (No updates)
- ▶ BONE DENSITY REGULATORS - PARATHYROID HORMONE DERIVATIVES (No updates)

# Archived Drug Classes

---

- ▶ BONE DENSITY REGULATORS : BISPHOSPHONATES (No updates)
- ▶ CARDIOVASCULAR AGENTS : ANTIANGINAL AGENTS - NITRATES (No updates)
- ▶ CARDIOVASCULAR AGENTS : ANTIANGINAL AGENTS – OTHER (No updates)
- ▶ CARDIOVASCULAR AGENTS : ANTIARRHYTHMICS (No updates)
- ▶ CARDIOVASCULAR AGENTS : CARDIAC GLYCOSIDES (No updates)
- ▶ CARDIOVASCULAR AGENTS : PERIPHERAL VASODILATORS – ORAL (No updates)
- ▶ CARDIOVASCULAR AGENTS : PHOSPHODIESTERASE INHIBITORS (No updates)
- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES – ORAL (No updates)

# Archived Drug Classes

---

- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES - ORAL, BIPHASIC  
(No updates)
- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES - ORAL,  
CONTINUOUS (No updates)
- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES - ORAL, EXTENDED  
CYCLE (No updates)
- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES - ORAL, TRIPHASIC  
(No updates)

# Archived Drug Classes

---

- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES - TRANSDERMAL
  - ▶ Twirla (Levonorgestrel-ethinyl estradiol)
    - ▶ FDA Approval: February 2020
- ▶ CONTRACEPTIVES : COMBINATION CONTRACEPTIVES – VAGINAL (No updates)
- ▶ CONTRACEPTIVES : COPPER CONTRACEPTIVES – IUD (No updates)
- ▶ CONTRACEPTIVES : EMERGENCY CONTRACEPTIVES (No updates)
- ▶ CONTRACEPTIVES : NON-PHARMACEUTICAL (No updates)
- ▶ CONTRACEPTIVES : PROGESTIN CONTRACEPTIVES - IMPLANTS (No updates)

# Archived Drug Classes

---

- ▶ CONTRACEPTIVES : PROGESTIN CONTRACEPTIVES – INJECTABLE (No updates)
- ▶ CONTRACEPTIVES : PROGESTIN CONTRACEPTIVES – IUD
  - ▶ Liletta (Levonorgestrel)
    - ▶ October 2019: FDA approved supplemental NDA to extend the use for up to six years
- ▶ CONTRACEPTIVES : PROGESTIN CONTRACEPTIVES – ORAL
  - ▶ Slynd (Drospirenone)
    - ▶ FDA Approval: May 2019
    - ▶ Only progestin only pill with a 24 hour intake window and 24 active + 4 inactive dosing regimen

# Archived Drug Classes

---

- ▶ CORTICOSTEROIDS : GLUCOCORTICOSTEROID COMBINATIONS (No updates)
- ▶ CORTICOSTEROIDS : MINERALOCORTICOIDS (No updates)
- ▶ COUGH / COLD : ANTITUSSIVES / EXPECTORANTS / MISC COMBINATIONS (No updates)
- ▶ COUGH / COLD : DECONGESTANTS – SYSTEMIC (No updates)
- ▶ COUGH / COLD : MISC (No updates)
- ▶ DERMATOLOGICS : ACNE PRODUCTS - ORAL (No updates)
- ▶ DERMATOLOGICS : ACNE PRODUCTS - TOPICAL (No updates)
- ▶ DERMATOLOGICS : AGENTS FOR EXTERNAL GENITAL AND PERIANAL WARTS (No updates)



# Archived Drug Classes

---

- ▶ DERMATOLOGICS : ANTINEOPLASTIC OR PREMALIGNANT LESION AGENTS - TOPICAL
  - ▶ Klisyri (Tirbanibulin)
    - FDA Approval: December 2020
    - Indicated actinic keratosis on face or scalp
- ▶ DERMATOLOGICS : ANTIPRURITICS – TOPICAL (No updates)
- ▶ DERMATOLOGICS : ANTIPSORIATICS – ORAL (No updates)
- ▶ DERMATOLOGICS : ANTIPSORIATICS - TOPICAL (No updates)
- ▶ DERMATOLOGICS : ANTISEBORRHEIC PRODUCTS (No updates)
- ▶ DERMATOLOGICS : BURN PRODUCTS (No updates)

# Archived Drug Classes

---

- ▶ DERMATOLOGICS : EMOLLIENTS & KEROLYTIC AGENTS (No updates)
- ▶ DERMATOLOGICS : ENZYMES - TOPICAL (No updates)
- ▶ DERMATOLOGICS : IMMUNOMODULATING AGENTS – TOPICAL (No updates)
- ▶ DERMATOLOGICS : KERATOLYTIC / ANTIMITOTIC AGENTS (No updates)
- ▶ DERMATOLOGICS : ROSACEA AGENTS
  - ▶ Zilxi (Minocycline micronized foam)
    - ▶ FDA Approval: May 2020
- ▶ DERMATOLOGICS : TOPICAL STEROIDS - HIGH POTENCY (No updates)

# Archived Drug Classes

---

- ▶ DERMATOLOGICS : TOPICAL STEROIDS - LOW POTENCY (No updates)
- ▶ DERMATOLOGICS : TOPICAL STEROIDS - MEDIUM POTENCY (No updates)
- ▶ DERMATOLOGICS : TOPICAL STEROIDS - VERY HIGH POTENCY (No updates)
- ▶ DERMATOLOGICS : WOUND CARE PRODUCTS - GROWTH FACTOR AGENTS (No updates)
- ▶ DIGESTIVE AIDS : PANCREATIC ENZYMES (No updates)
- ▶ DIURETICS : CARBONIC ANHYDRASE INHIBITORS (No updates)
- ▶ DIURETICS : DIURETIC COMBINATIONS (No updates)
- ▶ DIURETICS : LOOP DIURETICS (No updates)

# Archived Drug Classes

---

- ▶ DIURETICS : POTASSIUM SPARING DIURETICS (No updates)
- ▶ DIURETICS : THIAZIDE AND THIAZIDE-LIKE DIURETICS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ADENOSINE DEAMINASE SCID TREATMENT AGENTS – INJECTABLE (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ANABOLIC STEROIDS – ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ANDROGENS – OTHER (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ANTITHYROID AGENTS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : CALCIMIMETIC AGENTS - ORAL (No updates)

# Archived Drug Classes

---

- ▶ ENDOCRINE AND METABOLIC AGENTS : CARNITINE REPLENISHER AGENTS – ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : CORTICOTROPIN (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGEN / ANDROGEN COMBINATIONS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGEN / PROGESTIN COMBINATIONS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGEN / SELECTIVE ESTROGEN RECEPTOR MODULATOR COMBINATIONS (No updates)

# Archived Drug Classes

---

- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGENS - INJECTABLE (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGENS – ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGENS – TOPICAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : ESTROGENS – VAGINA (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : GROWTH HORMONE RECEPTOR ANTAGONISTS (No updates)

# Archived Drug Classes

---

- ▶ ENDOCRINE AND METABOLIC AGENTS : HYPOPHOSPHATASIA AGENTS - INJECTABLE (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : OXYTOCICS – ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : PHENYLKETONURIA (PKU) AGENTS - INJECTABLE (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : PHENYLKETONURIA (PKU) AGENTS - ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : POSTERIOR PITUITARY HORMONES - NASAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : POSTERIOR PITUITARY HORMONES - ORAL (No updates)

# Archived Drug Classes

---

- ▶ ENDOCRINE AND METABOLIC AGENTS : PROGESTERONE RECEPTOR ANTAGONISTS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : PROGESTERONES - VAGINAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : PROLACTIN INHIBITORS (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : THYROID HORMONE - ORAL (No updates)
- ▶ ENDOCRINE AND METABOLIC AGENTS : TRIPEPTIDYL PEPTIDASE 1 DEFICIENCY AGENTS (No updates)



# Archived Drug Classes

---

- ▶ ENDOCRINE AND METABOLIC AGENTS : X-LINKED HYPOPHOSPHATEMIA (XLH) AGENTS (No updates)
- ▶ GASTROINTESTINAL AGENTS - ULCER DRUGS : H-2 ANTAGONISTS
  - ▶ FDA requested withdrawal of all prescription and OTC ranitidine products from the market due to NDMA impurities (April 2020)
- ▶ GASTROINTESTINAL AGENTS - ULCER DRUGS : PROTON PUMP INHIBITORS (PPI) (No updates)
- ▶ GASTROINTESTINAL AGENTS : ANTIDIARRHEAL
  - ▶ FDA approved changes to packaging for name brand Imodium (loperamide) limiting carton to no more than 48 mg of loperamide and require tablets and capsules to be packaged individually to help address abuse and misuse

# Archived Drug Classes

---

- ▶ GASTROINTESTINAL AGENTS : GALLSTONE SOLUBILIZING AGENTS (No updates)
- ▶ GASTROINTESTINAL AGENTS : LAXATIVES (No updates)
- ▶ GASTROINTESTINAL AGENTS : OTHER (No updates)
- ▶ GASTROINTESTINAL AGENTS: ANTACIDS (No updates)
- ▶ GENITOURINARY AGENTS - MISC : ALKALINIZERS (No updates)
- ▶ GENITOURINARY AGENTS - MISC : URINARY ANALGESICS (No updates)
- ▶ GENITOURINARY AGENTS - MISC : URINARY ANTIINFECTIVES (No updates)
- ▶ GENITOURINARY AGENTS : ACIDIFIERS (No updates)

# Archived Drug Classes

---

## ▶ GENITOURINARY AGENTS : CYSTINOSIS AGENTS

### ▶ Procysbi (Cysteamine bitartrate)

- February 2020: New delayed-release oral granules in packets for adults and children one year of age and older

## ▶ GENITOURINARY AGENTS : INTERSTITIAL CYSTITIS AGENTS (No updates)

## ▶ GENITOURINARY AGENTS : URINARY STONE AGENTS (No updates)

## ▶ GI ULCER AGENTS : H. PYLORI ANTIBIOTICS

### ▶ Talicia (omeprazole + amoxicillin + rifabutin)

- FDA Approval: November 2019
- Indicated for the treatment of *Helicobacter pylori* infection in adults

## ▶ GI ULCER AGENTS : MISC (No updates)

# Archived Drug Classes

---

## ▶ GOUT AGENTS :

### ▶ Uloric (Febuxostat)

- ▶ February 2019: FDA requiring boxed warning be added to prescribing information for increased risk of death

## ▶ HEMATOLOGICAL AGENTS : OTHER (No updates)

## ▶ HEMATOLOGICAL AGENTS - MISC : ANTIHEMOPHILIC PRODUCTS

### ▶ Xyntha (antihemophilic factor- recombinant)

- ▶ August 2020: Expanded label to include new indication of routine prophylaxis to reduce the frequency of bleeding episodes in children and adults with hemophilia A

### ▶ Esperoct (antihemophilic factor- recombinant, glycopegylated-exei)

- ▶ FDA Approval: February 2019

# Archived Drug Classes

---

## ▶ HEMATOLOGICAL AGENTS - MISC : ANTIHEMOPHILIC PRODUCTS (cont.)

- ▶ Wilate (antihemophilic factor VIII/Von Willebrand factor- human)
  - October 2019: Expanded label to include new indication of routine prophylaxis to reduce the frequency of bleeding episodes and on demand treatment and control of bleeding episodes
- ▶ Sevenfact (coagulation factor VIIa-jncw)
  - FDA Approval: April 2020
  - Indicated for the treatment and control of bleeding episodes in adults and adolescent 12 years of age and older with hemophilia A or B with inhibitors.
- ▶ Ixinity (coagulation factor IX recombinant)
  - September 2020: Expanded label to include new indication for routine prophylaxis to reduce the frequency of bleeding episodes in adults and adolescents 12 years or age and older with hemophilia B

# Archived Drug Classes

---

- ▶ HEMATOLOGICAL AGENTS - MISC : COMPLIMENT INHIBITORS
  - ▶ Soliris (eculizumab)
    - FDA Approval: June 2019
    - Indicated for the treatment of neuromyelitis optica spectrum disorder
- ▶ HEMATOLOGICAL AGENTS : PLATELET AGGREGATION INHIBITORS (No updates)
- ▶ HEMATOPOIETIC AGENTS : COBALAMINS / COBALAMIN COMBINATIONS (No updates)
- ▶ HEMATOPOIETIC AGENTS : FOLIC ACID / FOLATE COMBINATIONS (No updates)
- ▶ HEMATOPOIETIC AGENTS : IRON / IRON COMBINATIONS (No updates)

# Archived Drug Classes

---

- ▶ HEMOSTATICS : SYSTEMIC – INJECTABLE (No updates)
- ▶ HEMOSTATICS : SYSTEMIC – ORAL (No updates)
- ▶ IMMUNOSUPPRESSIVE AGENTS : CYCLOSPORINE ANALOGS – ORAL
  - ▶ Lupkynis (Voclosporine)
    - FDA Approval: January 2021
    - Indicated for treatment of adult patients with active lupus nephritis
- ▶ IMMUNOSUPPRESSIVE AGENTS : INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS – ORAL (No updates)
- ▶ IMMUNOSUPPRESSIVE AGENTS : MACROLIDE IMMUNOSUPPRESSANTS (No updates)

# Archived Drug Classes

---

## ▶ IMMUNOSUPPRESSIVE AGENTS : MONOCLONAL ANTIBODIES

### ▶ Enspryng (satralizumab-mwge)

➤ FDA Approval: August 2020

➤ Indicated for the treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 (AQP4) antibody positive

## ▶ IMMUNOSUPPRESSIVE AGENTS : PURINE ANALOGS (No updates)

## ▶ MIGRAINE AGENTS : ERGOT DERIVATIVES (No updates)

## ▶ MIGRAINE AGENTS : OTHER (No updates)

## ▶ MINERALS AND ELECTROLYTES : CALCIUM – ORAL (No updates)

## ▶ MINERALS AND ELECTROLYTES : FLUORIDE – ORAL (No updates)



# Archived Drug Classes

---

- ▶ MINERALS AND ELECTROLYTES : PHOSPHATE – ORAL (No updates)
- ▶ MINERALS AND ELECTROLYTES : POTASSIUM (No updates)
- ▶ MISCELLANEOUS THERAPEUTIC CLASSES : CHELATING AGENTS – ORAL (No updates)
- ▶ MOUTH / THROAT / DENTAL AGENTS : ARTIFICIAL SALIVA (No updates)
- ▶ MOUTH / THROAT / DENTAL AGENTS : SALIVA STIMULANTS (No updates)
- ▶ MUSCULOSKELETAL THERAPY AGENTS : SKELETAL MUSCLE RELAXANTS (No updates)

# Archived Drug Classes

---

## ▶ NEUROLOGICAL AGENTS : OTHER

### ▶ Xywav (calcium, magnesium, potassium, and sodium oxybates)

➤ FDA Approval: July 2020

➤ Indicated for cataplexy and excessive daytime sleepiness in patients seven years of age and older with narcolepsy

## ▶ NEUROLOGICAL AGENTS : TRANSTHYRETIN AMYLOIDOSIS AGENTS (No updates)

## ▶ NEUROMUSCULAR AGENTS : ALS AGENTS – BENZATHIAZOLES (No updates)

## ▶ NEUROMUSCULAR AGENTS : ALS AGENTS - MISC (No updates)

## ▶ ONCOLOGY AGENTS : ANTINEOPLASTIC PROGESTINS - ORAL (No updates)

# Archived Drug Classes

---

- ▶ ONCOLOGY AGENTS : AROMATASE INHIBITORS – ORAL (No updates)
- ▶ ONCOLOGY AGENTS : AUTOLOGOUS CELLULAR IMMUNOTHERAPY (No updates)
- ▶ ONCOLOGY AGENTS : CHEMOTHERAPY RESCUE / ANTIDOTE AGENTS - URINARY TRACT PROTECTIVE AGENTS – ORAL (No updates)
- ▶ ONCOLOGY AGENTS : FOLIC ACID ANTAGONISTS RESCUE AGENTS – ORAL (No updates)
- ▶ ONCOLOGY AGENTS : RADIOPHARMACEUTICALS (No updates)
- ▶ OPHTHALMIC AGENTS : ANTIALLERGIC (No updates)

# Archived Drug Classes

---

- ▶ OPHTHALMIC AGENTS : ANTIBIOTICS (No updates)
- ▶ OPHTHALMIC AGENTS : ANTIBIOTICS – SULFONAMIDES (No updates)
- ▶ OPHTHALMIC AGENTS : ANTIBIOTIC-STEROID COMBINATIONS(No updates)
- ▶ OPHTHALMIC AGENTS : ANTIFUNGALS (No updates)
- ▶ OPHTHALMIC AGENTS : ANTIVIRALS (No updates)
- ▶ OPHTHALMIC AGENTS : ARTIFICIAL TEARS AND LUBRICANTS (No updates)
- ▶ OPHTHALMIC AGENTS : CYCLOPLEGIC MYDRIATICS (No updates)

# Archived Drug Classes

---

## ▶ OPHTHALMIC AGENTS : CYSTINOSIS AGENTS

### ▶ Cystadrops (Cysteamine)

➤ FDA Approval: August 2020

➤ Indicated for treatment of corneal cystine-crystal deposits in adults and children with cystinosis

➤ Four times per day dosing

## ▶ OPHTHALMIC AGENTS : DECONGESTANTS (No updates)

## ▶ OPHTHALMIC AGENTS : GENE THERAPY (No updates)

## ▶ OPHTHALMIC AGENTS : LOCAL ANESTHETICS (No updates)

## ▶ OPHTHALMIC AGENTS : NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (No updates)

# Archived Drug Classes

---

- ▶ OPHTHALMIC AGENTS : STEROIDS – TOPICAL (No updates)
- ▶ OTIC AGENTS : ANALGESICS COMBINATIONS (No updates)
- ▶ OTIC AGENTS : ANTI-INFECTIVES (No updates)
- ▶ OTIC AGENTS : MISC (No updates)
- ▶ OTIC AGENTS : STEROIDS (No updates)
- ▶ RESPIRATORY AGENTS : ALPHA-PROTEINASE INHIBITOR (HUMAN) (No updates)
- ▶ SLEEP DISORDER AGENTS : BARBITURATE HYPNOTICS (No updates)
- ▶ SLEEP DISORDER AGENTS : BENZODIAZEPINE HYPNOTICS

# Archived Drug Classes

---

- ▶ SLEEP DISORDER AGENTS : BENZODIAZEPINE HYPNOTICS
  - ▶ September 2020: FDA requiring Boxed Warning be updated describing risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions with benzodiazepines.
- ▶ SMOKING DETERRENTS : NICOTINE REPLACEMENT PRODUCTS (No updates)
- ▶ SUBSTANCE USE DISORDER : ALCOHOL DETERRENTS (No updates)
- ▶ VITAMINS : B-COMPLEX VITAMINS (No updates)
- ▶ VITAMINS : PEDIATRIC – MULTIVITAMINS (No updates)
- ▶ VITAMINS : PEDIATRIC - VITAMINS A/D/C (No updates)

# Archived Drug Classes

---

- ▶ VITAMINS : PRENATAL VITAMINS (No updates)
- ▶ VITAMINS : VITAMIN B-1 (No updates)
- ▶ VITAMINS : VITAMIN B-6 (No updates)



# Archived Drug Classes

---

## ▶ Recommendation:

- ▶ All drug classes listed on slides 2 through 40 are eligible for archiving at the discretion of HCA.
- ▶ Products in these drug classes may require prior authorization to determine medical necessity
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

# Archived Drug Classes

---

▶ **Motion:** I move that all drug classes listed on slides 2 through 40 are eligible for archiving at the discretion of HCA. Products in these drug classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▶ **Motion:**

▶ **2<sup>nd</sup>:**